Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management
Authors: Spelta Caroline
Journal: Veterinary Medicine: Research and Reports
Summary
# Editorial Summary: Equine Pituitary Pars Intermedia Dysfunction – Diagnosis and Management Equine PPID represents a progressive neurodegenerative condition affecting the hypothalamus, characterised by loss of dopaminergic control over the pars intermedia, though the underlying oxidative stress mechanism remains unclear. Diagnosis of early and subclinical disease continues to challenge practitioners, as traditional tests such as overnight dexamethasone suppression have proven far less reliable than initially thought—whilst showing 100% sensitivity and specificity in advanced cases, they fail to detect disease in earlier stages. Basal adrenocorticotropin sampling during autumn months offers improved diagnostic accuracy, and α-melanocyte-stimulating hormone shows considerable promise as a single-sample test, though current commercial unavailability limits its practical application. Beyond the classical presentation of hypertrichosis, the emerging understanding of PPID's association with hyperinsulinemia and secondary laminitis has become a significant focus, as these complications substantially impact welfare and prognosis. Pergolide mesylate remains the primary medical intervention, with recent pharmacokinetic and survival data now available to guide treatment protocols and inform owners of realistic long-term outcomes.
Read the full abstract on PubMed
Practical Takeaways
- •Don't rely solely on the dexamethasone suppression test for early PPID diagnosis—consider basal ACTH sampling in autumn for better detection of subclinical disease
- •Hyperinsulinemia and laminitis are common concurrent findings in PPID cases; screen for insulin dysfunction when managing PPID patients
- •Pergolide mesylate remains the primary medical treatment; recent pharmacokinetic and long-term outcome data now support clinical decision-making
Key Findings
- •Overnight dexamethasone suppression test shows reduced sensitivity and specificity for early PPID detection despite 100% accuracy in advanced disease
- •Basal plasma ACTH concentrations improve diagnostic sensitivity and specificity when sampled during autumn months
- •α-melanocyte-stimulating hormone shows promise as a sensitive and specific single-sample diagnostic test, though not yet commercially available
- •Strong association exists between laminitis, hyperinsulinemia, and PPID, representing a focus of current research